A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease

Neurobiology of Aging

Volumn 19, Issue 6, 1998, Pages 505-510

  Salehi, A ^a   Gonzalez Martinez, V ^a   Swaab, D F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Alz 50; Alzheimer's disease; ApoE; Neurofibrillary tangles; Sex difference; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; MALE; MORPHOMETRICS; NEUROFIBRILLARY TANGLE; OLIVARY NUCLEUS; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIGENS; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; SEX CHARACTERISTICS; SEX FACTORS; SUBSTANTIA INNOMINATA;

EID: 0032450835     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(98)00106-7     Document Type: Article

References (56)

1. 1. Arnold, S. E.; Hyman, B. T.; Flory, J.; Damasio, A. R.; Van Hoesen, G. W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in patients with Alzheimer's disease. Cereb. Cortex 1:103-116; 1991.
2. 2. Arriagada, P. V.; Growdon, J. H.; Hedley-Whyte, E. T.; Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel severity of Alzheimer's disease. Neurology 42:631-639; 1992.
3. 3. Bondareff, W.; Wischik, C. M.; Novak, M.; Amos, W. B.; Klug, A.; Roth, M. Molecular analysis of neurofibrillary degeneration in Alzheimer's disease. Am. J. Pathol. 137:711-723; 1990.
4. 4. Braak, E.; Braak, H. Alzheimer's disease: Transiently developing dendritic changes in pyramidal cells of sector CAI of the Ammon's horn. Acta Neuropathol. 93:323-325; 1997.
5. 5. Braak, H.; Braak, E. Neuropil threads occur in dendrites of tangle-bearing nerve cells. Neuropathol. Appl. Neurobiol. 14:39-44; 1988.
6. 6. Braak, H.; Braak, E.; Grundke Iqbal, I.; Iqbal, K. Occurrence of neuropil threads in the senile human brain and Alzheimer's disease: A third location of paired helical of neurofibrillary tangles and neuritic plaques. Neurosci. Lett. 65:351-355; 1986.
7. 7. Bramblett, G. T.; Goedert, M.; Jakes, R.; Merrick, S. E.; Trojanowski, J. Q.; Lee, V. M. Abnormal tau phosphorylation at Ser396 in Alzheimer's recapitulates development and contributes to reduced binding. Neuron 10:1089-1099; 1993.
8. 8. Brayne, C.; Gill, C.; Huppert, F. A.; Barkley, C.; Gehlhaar, E.; Girling, D. M.; Paykel, E. S. Incidence of clinically diagnosed subtypes of dementia in an elderly population. Br. J. Psychiatry 167:255-262; 1995.
9. 9. Bullido, M. J.; Artiga, M. J.; Recuero, M.; Sastre, I.; Garcia, M. A.; Aldudo, J.; et al. A polymorphism in the regulatory region of APOE associated with risk of Alzheimer's dementia. Nat. Genetics, 18:69-71; 1998.
10. 10. Camel, G.; Mager, E. M.; Binder, L. I.; Kuret, J. The structural basis of monoclonal antibody AI/50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271:32789-32795; 1996.
11. 11. Corder, E. H.; Saunders, A. M.; Risch, N. J.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C., Jr.; Rimmler, J. B.; Locke, P. A.; Conneally, P. M.; Schmader, K. E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7:180-184; 1994.
12. 12. Fratiglioni, L.; Viitanen, M.; VonStrauss, E.; Winblad, B. Late-onset Alzheimer's disease: Incidence data from the Kungsholmen project, Stockholm. In: Iqbal, L.; Winblad, B.; Nishimura, T.; Takeda, M.; Wisniewski, H. M., eds. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Chichester, UK: John Wiley & Sons; 1997;49-53.
13. 13. Gearing, M.; Mori, H.; Mirra, S. S. A β-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39:395-399; 1996.
14. 14. Goedert, M.; Spillantini, M. G.; Jakes, R. Localization of the Alz-50 epitope in recombinant human microtubule-associated protein tau. Neurosci. Lett. 126:149-154; 1991.
15. 15. Gomez-Isla, T.; West, H. L.; Rebeck, G. W.; Harr, S. D.; Growdon, J. H.; Locascio, J. J.; Perls, T. T.; Lipsitz, L. A.; Hyman, B. T. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann. Neurol. 39:62-70; 1996.
16. 16. Growdon, J. H.; Lacascio, J. J.; Corkin, S.; et al. Apolipoprotin E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 47:444-448; 1996.
17. 17. Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:154-159; 1997.
18. 18. Honjo, H.; Ogino, Y.; Naitoh, K.; Urahe, M.; Kitawaki, J.; Yasuda, J.; Yamamoto, T.; Ishihara, S.; Okada, H.; Yonezawa, T.; et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J. Steroid Biochem. 34:521-525; 1989.
19. 19. Hyman, B. T.; Van Hoesen, G. W.; Wolozin, B. L.; Davies, P.; Kromer, L. J.; Damasio, A. R. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann. Neurol. 23:371-379; 1988.
20. 20. Ksiezak Reding, H.; Binder, L. I.; Yen, S. H. Alzheimer disease proteins (A68) share epitopes with tau but show distinct biochemical properties. J. Neurosci. Res. 25:420-430; 1990.
21. 21. Kurz, A.; Egensperger, R.; Haupt, M.; Lautenschlager, N.; Romero, B.; Graeber, M. B.; Muller, U. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Arch. Neurol. 47:440-443; 1996.
22. 22 Lee, V. M.; Balin, B. J.; Otvos, L., Jr.; Trojanowski, J. Q. A68: A major subunit of paired helical filaments and forms of normal Tau. Science 251:675-678; 1991.
23. 23. Lee, V. M.; Trojanowski, J. Q. The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2:653-656; 1992.
24. 24. Lee, V. M.-Y. Disruption of the cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 5:663-668; 1995.
25. 25. Lovestone, S.; Anderton, B. H.; Hartley, C.; Jensen, T. G.; Jorgensen, A. L. The intracellular fate of apolipoprotein E is tau dependent and apoE allele-specific. Neuroreport 7:1005-1008; 1996.
26. 26 McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E. Clinical diagnosis of Alzheimer's disease: Report of NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 34:939-944; 1984.
27. 27. McMillan, P. J.; Singer, C. A.; Dorsa, D. M. The effects of ovariectomy and estrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. J. Neurosci. 16:1860-1865; 1996.
28. 28. Mesulam, M.-M.; Mufson, E. J.; Levey, A.; Wainer, B. H. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei. nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 214:170-197; 1983.
29. 29. Mukactova-Ladinska, E. B.; Harrington, C. R.; Roth, M.; Wishik, C. M. Presence of the apolipoprotein E type ∈4 alleles is not associated with neuroFibrillary pathology or biochemical changes to tau protein. Dement. Geriat. Cogn. Disord. 8:288-295; 1997.
30. 30. Nagy, Z.; Esiri, M. M.; Jobst, K. A.; Johanston, C.; Litchhfield, S.; Sim, E.; Smith, A. D. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69:757-761; 1995.
31. 31. Paganini Hill, A. Oestrogen replacement therapy and Alzheimer's disease. Br. J. Obstet. Gynaecol. Suppl. 13:80-86; 1996.
32. 32. Paganini-Hill, A.; Henderson, V. W. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:256-261; 1994.
33. 33. Payami, H.; Montee, K. R.; Kaye J. A.; Bird, T. D.; Yu, C.-E.; Wijsman, E. M.; Shellenberg, G. D. Alzheimer's disease, apolipoprotein e4 a, apolipoprotein e4 and gender. JAMA 271:1316-1317; 1994.
34. 34. Payami, H.; Zareparsi, S.; Montee, K. R.; Sexton, C. J.; kaye, J. A.; Bird, T. D.; Yu, C.-E.; Wijsman, E. M.; Heston, L. L.; Lati, M.; Shellenberg, G. D. Gender differences in apolipoprotein E-associated risk for familial Alzheimer disease: A possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet. 58:803-811; 1996.
35. 35. Poirier, I.; Delisle, M. C.; Quirion, R.; Aubert, I.; Farlow, M.; Iahiri, D.; Hui, S.; Bertrand, P.; Nalbantoglu, J.; Gilfis, B.; et al. Apolipoprotein e4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92: 12260-12264; 1995.
36. 36. Poirier, J.; Nalbantoglu, J.; Guillaume, D.; Bertrand, P. Apolipoprotein E and Alzheimer's disease. In: Goate, A.; Ashall, F., eds. Pathobiology of Alzheimer's Disease. New York: Academic Press; 1995:225-245.
37. 37. Rebeck, G. W.; Reiter, J. S.; Strickl, D. K.; Hyman, B. T. Apolipoprotein E in sporadic Alzheimer's disease: Allelic and receptor interactions. Neuron 11:575-580; 1993.
38. 38. Rebeck, G. W, Perls, T. T, West, H. L.; et al. Reduced apolipoprotein ∈4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology 144:1513-1516; 1994.
39. 39. Reisberg, B.; Ferris, S. H.; de Leon, M. J.; Crook, T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139:1136-1139; 1982.
40. 40. Roses, A. D. Apolipoprotein E affects the rate of Alzheimer disease -amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53:429-437; 1994.
41. 41. Rye, D. B.; Leverenz, J.; Greenberg, S. G.; Davies, P.; Saper, C. B. The distribution of Alz-50 immunoreactivity in the normal brain. Neuroscience 56:109-127; 1993.
42. 42. Salehi, A.; Lucassen, P. J.; Pool, C. W.; Gonatas, N. K.; Ravid, R.; Swaab, D. F. Decreased neuronal activity in the nucleus basalis of Alzheimer's disease as suggested by the size of the Golgi apparatus. Neuroscience 59:871-880; 1994.
43. 43. Salehi, A.; Van de Nes, J. A.; Hofman, M. A.; Gonatas, N. K.; Swaab, D. F. Early cytoskeletal changes as shown by Alz-50 are not accompanied by decreased neuronal activity. Brain Res. 678:28-39; 1995.
44. 44. Salehi, A.; Dubelaar, E. J.; Mulder, M.; Swaab D. F. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc. Natl. Acad. Sci. USA 95:11445-11449; 1998.
45. 45. Saunders, A. M.; Schmader, K.; Breitner, J. C.; Benson, M. D.; Brown, W. T.; Goldfarb, L.; Goldgaber, D.; Manwaring, M. G.; Szymanski, M. H.; McCown, N.; et al. Apolipoprotein E epsilon 4 allele distributions in Alzheimer's disease and in other amyloid-forming diseases. Lancet 342:710-711; 1993.
46. 46. Schmechel, D. E.; Saunders, A. M.; Strittmatter, W. J.; Crain, B. J.; Huleite, C. M.; Joo, S. H.; Pericak-Vance, M. A.; Goldgaber, D.; Roses, A. D. Increased amyloid β-peptide deposition in cerebral consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90:9649-9653; 1993.
47. 47. Strittmatter, W. J.; Weisgraber, K. H.; Goedert, M.; Saunders, A. M.; Huang, D.; Corder, E. H.; Dong, L. M.; Jakes, R.; Alberts, M. J.; Gilbert, J. R.; et al. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125:163-171; 1994.
48. 48. Swaab, D. F.; Grundke-Iqbal, I.; Iqbal, K.; Kremer, H. P.; Ravid, R.; Van de Nes, J. A. Tau and ubiquitin in the human hypothalamus in aging and disease. Brain Res. 590:239-249; 1992.
49. 49. Toran-Allerand, C. D. Mechanisms of estrogen action during neural development: Mediation by interactions with the neurotrophins and their receptors. J. Steroid Biochem. Mol. Biol. 56:169-178; 1996.
50. 50. Ueda, K.; Masliah, E.; Saitoh, L.; Bakalis, S. L.; Scoble, H.; Kosik, K. S. Alz-50 recognizes a phosphorylated epitope of tau protein. J. Neurosci. 10:3295-3304; 1990.
51. 51. Van de Nes, J. A.; Kamphorst, W.; Ravid, R.; Swaab, D. F. The distribution of Alz-50 immunoreactivity in the adjoining areas of Alzheimer's disease patients. Brain 116(Pt 1):103-115; 1993.
52. 52. Van de Nes, J. A.; Sluiter, A. A.; Pool, C. W.; Kamphorst, W.; Ravid, R.; Swaab, D. F. The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal hypothalamus and adjoining areas. Brain Res. 655:97-109; 1994.
53. 53. Wenham, P. R.; Price, W. H.; Blundell, G. Apolipoprotein E genotyping by one-stage PCR. Lancet 337:1157-1159; 1991.
54. 54. Wisniewski, T.; Golabek, A.; Matsubara, E.; Ghiso, J.; Frangione, B. Apolipoprotein E. binding to soluble Alzheimer's disease. Biochem. Biophys. Res. Commun. 192:359-365; 1993.
55. 55. Wolozin, B. L.; Pruchnicki, A.; Dickson, D. W.; Davies, P. A neuronal antigen in the brains of Alzheimer patients. Science 232:648-650; 1986.
56. 56. Wolozin, B.; Davies, P. Alzheimer-related neuronal protein A68: Specificity and distribution. Ann. Neurol. 22:521-526; 1987.